WAM
AGIO icon

Wealthspire Advisors (Maryland)’s Agios Pharmaceuticals AGIO Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-32
Closed -$2K – 495
2019
Q1 		$2K Buy
32
+3
+10% +$175 ﹤0.01% 2110
2018
Q4 		$1K Buy
29
+7
+32% +$432 ﹤0.01% 2211
2018
Q3 		$2K Sell
22
-22
-50% -$1.77K ﹤0.01% 2120
2018
Q2 		$4K Buy
44
+24
+120% +$2.09K ﹤0.01% 1848
2018
Q1 		$2K Buy
20
+15
+300% +$1.16K ﹤0.01% 2124
2017
Q4 		$0 Sell
5
-12
-71% -$755 ﹤0.01% 2424
2017
Q3 		$1K Buy
17
+10
+143% +$601 ﹤0.01% 2052
2017
Q2 		$0 Buy
7
+3
+75% +$153 ﹤0.01% 2183
2017
Q1 		$0 Hold
4
– – ﹤0.01% 1908
2016
Q4 		$0 Hold
4
– – ﹤0.01% 1743
2016
Q3 		$0 Hold
4
– – ﹤0.01% 1723
2016
Q2 		$0 Hold
4
– – ﹤0.01% 1682
2016
Q1 		$0 Buy
+4
New +$171 ﹤0.01% 1732

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s AGIO Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Agios Pharmaceuticals (AGIO) in Q2 2019, closing a stake of 32 shares — an estimated $2K sold.

Wealthspire Advisors (Maryland) first reported a position in AGIO in Q1 2016 and held it in 13 quarters. The position peaked at $4K in Q2 2018. 189 funds tracked by Wall St. Rank hold AGIO as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Agios Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 32 Agios Pharmaceuticals shares in Q2 2019, an estimated $2K.
  • Wealthspire Advisors (Maryland) first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 13 quarters.
  • Wealthspire Advisors (Maryland)'s Agios Pharmaceuticals position peaked at $4K in Q2 2018.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.